HER2/neu over-expression induces endothelial cell retraction

Area of Science:

• Oncology
• Cell Biology
• Cancer Metastasis Research

Background:

• Over-expression of the HER2/neu (HER2) proto-oncogene is linked to increased breast carcinoma metastatic potential.
• Tumor cell metastasis involves transmigration across endothelial cell (EC) monolayers, a process potentially preceded by EC retraction.

Purpose of the Study:

• To investigate the role of HER2 signaling in inducing endothelial cell retraction by breast cancer cells.
• To determine if HER2 signaling influences cancer cell-induced EC retraction and subsequent matrix exposure.

Main Methods:

• Co-culture of MCF-7 breast cancer cells and HER cells (MCF-7 over-expressing HER2) with human iliac vein EC monolayers.
• Quantification of EC retraction and subendothelial matrix exposure.
• Assessment of HER2 signaling blockade (Herceptin) and stimulation (heregulin-beta1) effects on EC retraction.
• Evaluation of cell adhesion and adherence strength under shear stress.

Main Results:

• HER cells induced significantly more EC retraction (76%) and matrix exposure (6.80%) compared to MCF-7 cells (17% and 0.85%, respectively).
• Herceptin blockade of HER2 signaling nearly eliminated EC retraction, while heregulin-beta1 stimulation augmented it.
• No significant differences were observed in cell adhesion or adherence strength between cell lines under shear stress.

Conclusions:

• HER2 signaling in breast cancer cells actively promotes endothelial cell retraction.
• This HER2-mediated EC retraction facilitates exposure of the subendothelial matrix, a key step preceding tumor cell transmigration and metastasis.
• Targeting HER2 signaling may offer a therapeutic strategy to inhibit breast cancer metastasis.